Barrington Research Cuts Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX) – Equities research analysts at Barrington Research lowered their Q2 2025 earnings per share (EPS) estimates for Surmodics in a research note issued to investors on Friday, January 31st. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Barrington Research also issued estimates for Surmodics’ Q3 2025 earnings at $0.08 EPS.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

A number of other equities analysts have also commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. StockNews.com initiated coverage on Surmodics in a research report on Monday. They set a “hold” rating for the company. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $50.00.

Surmodics Price Performance

Shares of SRDX stock opened at $33.62 on Monday. The stock’s fifty day simple moving average is $38.47 and its 200 day simple moving average is $39.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The firm has a market cap of $480.77 million, a price-to-earnings ratio of -33.29 and a beta of 1.20. Surmodics has a one year low of $25.17 and a one year high of $42.44.

Insider Activity at Surmodics

In other news, CFO Timothy J. Arens sold 7,009 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now owns 70,350 shares in the company, valued at approximately $2,774,604. This trade represents a 9.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.90% of the company’s stock.

Institutional Investors Weigh In On Surmodics

A number of large investors have recently modified their holdings of SRDX. Modus Advisors LLC bought a new stake in Surmodics during the 4th quarter worth $40,000. Quest Partners LLC grew its position in shares of Surmodics by 107,100.0% in the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after buying an additional 1,071 shares during the last quarter. R Squared Ltd bought a new stake in shares of Surmodics in the 4th quarter valued at about $55,000. Longfellow Investment Management Co. LLC acquired a new position in shares of Surmodics in the 3rd quarter valued at about $67,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Surmodics in the 2nd quarter valued at about $229,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).